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Abstract
Background: Tuberculosis (TB) remains a debilitating, deadly disease that warrants innovative research tools to fully
understand the pathogenesis and host immune responses, particularly at the site of infection and disease. In this
regard, bronchoscopies with bronchoalveolar lavage (BAL) serve as a valuable technique for site of disease sample
retrieval for further clinical- and basic research. Here we investigate the feasibility of research bronchoscopies in a
low/middle-income area, where TB remains rife, and assess the value of retrieved BAL cells (BALC) for downstream
fluorescent-based cellular evaluations.
Methods: Using quantitative and qualitative methods, we evaluate the outcomes, safety, tolerability, participant
-perception and -experience, while also providing insight into participant recruitment and screening processes of
our study. Using light microscopy differential counting for BALC analysis, we evaluate the cellular composition of
BAL fluid (BALF) from TB patients, healthy community controls and patients with other lung diseases. We also use
flow cytometry to describe the challenges associated with fluorescence-based phenotypic analysis of
autofluorescent BALC.
Results: Our findings suggest that research bronchoscopies are safe, acceptable procedures for research
participants and are indeed a feasible technique for future study design. We also suggest that the majority of
participants are receptive to the proposition of a second research bronchoscopy. This poses an important avenue
for research entailing follow-up investigations of the same study participant. Furthermore, our results show that
smoking is characterized by retrieval of BALC containing particulate matter, that interferes with fluorescence-based
flow cytometry data analysis. Based on light microscopy differential cell counting, our findings suggest that there
are differences in the cell yields and cellular composition of the BALF between TB patients, healthy community
controls and patients with other lung diseases. We also report on subject characteristics and demographic factors,
namely gender and age, that have the potential to affect cell yields and cellular data of BALF.
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Conclusions: These findings will serve as a valuable reference for appropriate planning and design of studies
involving clinical bronchoscopies for TB and lung disease research.
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Introduction
Bronchoscopies are widely performed as part of the
clinical workup of lung disease, including the diagnosis
and grading of cancerous lung lesions and identification
of lung pathogens. It is thought that the cellular patterns
in bronchoalveolar lavage (BAL) fluid (BALF) also reflect
immune processes and host responses within the lung
airways, hence its increasing popularity in the pulmon-
ary research field [1–5]. In this way, BAL samples allow
researchers to investigate cellular responses directly
from the affected region with relatively low to moderate
risk, to gain a better understanding of the underlying
pathophysiological mechanisms of lung disease.
Tuberculosis (TB) remains the leading cause of death
due to infectious disease, caused by the Mycobacterium
tuberculosis (Mtb) bacilli [6]. Mtb is most widely known
for manifesting in the lung, leading to pulmonary TB
(PTB) disease. For this reason, BAL procedures are of
particular interest to TB researchers, however, relatively
little has been published in this regard, compared to
more easily accessible sample types such as blood, saliva,
sputum and urine. Although bronchoscopy has common
diagnostic or therapeutic indications, it is perceived as
less acceptable when performed for research purposes,
with no direct patient benefit.
Despite being considered as a safe procedure when
performed by a skilled professional in the absence of
contra-indications, bronchoscopies remain an invasive
technique necessitating operator proficiency, established
operating procedures that include safety measures and
well-equipped facilities. A study by Poi and colleagues
reported that 58% of study participants expressed fear of
undergoing bronchoscopy [7]. However, another re-
search bronchoscopy study demonstrated that the
procedure was well-tolerated and did not negatively in-
fluence participants’ future decisions regarding health
care-seeking behavior [8]. A review by Martinsen et al.,
evaluating research bronchoscopy participation, identi-
fied seven relevant studies, of which six were conducted
in Europe. This highlighted the need for further insight
into subject participation in research bronchoscopy
studies, particularly in low to middle-income countries
such as South Africa [9].
In the current study, we address the clinical feasibility
and practical aspects concerning research bronchosco-
pies in the Western Cape, a highly TB burdened region
in South Africa. Considering the importance for research
bronchoscopies to be time- and cost-effective, safe and
acceptable to the population of interest, we evaluate the
safety, tolerability, participant -perception and -experi-
ence, while also providing insight into participant
recruitment and screening processes. We summarize our
assessment of the feasibility of research bronchoscopies
and provide expected reference ranges for BAL cell
(BALC) and BALF retrieval and composition from TB
patients, healthy community controls and patients
suffering from non-TB related lung disease in the con-
text of the social, economic, and health setting of the
Western Cape region, a setting with both affluent and
poor socio-economic societies. Lastly, we discuss prob-
lems associated with fluorescence-based phenotyping of
BALC from smoking participants.
Materials and methods
Study population
Study participants were HIV-infected and uninfected
adults between the ages of 18 and 80, who volunteered
to be enrolled in a research bronchoscopy study from
2016 to 2018. All healthy community controls (“healthy”
group), participants in close contact with an active TB
patient (“TB contacts”) and all but one of the PTB patients
(“TB cases”) were HIV-uninfected individuals. The HIV-
infected TB case presented with extra-pulmonary TB.
All active TB cases, TB contacts and healthy commu-
nity controls underwent a chest x-ray (CXR) as part of
the initial screening. Only participants with CXR
findings that did not preclude unsafe performance of
bronchoscopy, a Karnofsky score of > 60%, no evidence
of severe aneamia (Hb > 9 g/dl) and no serious systemic
condition that, in the opinion of the study clinician,
would make the performance of a bronchoscopy unsafe
were included in the study. Active TB cases presented
with clinical, culture, GeneXpert and radiographic
results characteristic of pulmonary TB disease. At the
time of bronchoscopy, TB cases received less than seven
doses of anti-tuberculosis treatment. Healthy community
control subjects were recruited from the same commu-
nities as TB cases but had no clinical, radiological or
mycobacterial evidence of TB disease or other diseases
detected by clinical examination, medical history or by
screening medical tests, that included a fingerprick ran-
dom glucose and hemoglobin test. TB contacts included
participants with close contact with an active PTB
patient for at least 1 month prior to TB diagnosis and
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included participants with or without diabetes mellitus
(DM). The subset of participants with DM (confirmed
by HbA1c ≥7%) included in the TB contacts group, had
no history of a recent myocardial infarction or any signs
of myocardial ischemia on electrocardiogram (ECG).
TB cases, TB contacts and healthy community con-
trols had no clinical indication for bronchoscopy and
bronchoscopies were done for research purposes only.
Other lung disease (OLD) participants were recruited
from the Pulmonology Division of Tygerberg Academic
Hospital (TBH) and had clinical indications for bron-
choscopy. OLD participants presented with a variety of
respiratory conditions including, lung infiltrations, un-
identified lesions, sarcoidosis or other symptoms of
respiratory disease.
Clinical cases were not included in the bronchoscopy
procedure discussion, since they had clinical indications
for bronchoscopy and the procedure was performed and
monitored by TBH staff, rather than our research clini-
cians. Analysis and discussion of BALC data included
the OLD cohort and a subset of TB participants and
healthy community controls (Fig. 1). Written informed
consent was obtained from participants and study de-
sign was approved by the Stellenbosch University Ethics
Review Committee (IRB number N16/05/070 and N13/
05/064).
Bronchoscopy procedure
The bronchoscopy procedure was standardized for all
research participants, derived from the British Thoracic
society guidelines on diagnostic flexible bronchoscopy
[10]. Bronchoscopies were performed by a skilled endos-
copists in the bronchoscopy theatre of a tertiary hospital
in the Western Cape Province of South Africa, Tyger-
berg Hospital. All participants received topical ligno-
caine spray in the larynx and nasal mucosa, and were
Fig. 1 Standards for reporting of diagnostic accuracy (STARD) diagram illustrating study design and participant classification. TB group
encompassed confirmed PTB patients with radiographical evidence, positive GeneXpert and confirmed Mtb sputum culture. Healthy community
controls had no evidence of TB or other diseases. TB Contacts group had close contact with an active TB patient and included a subset of 12
participants with Diabetes Mellitus. OLD group presented with various respiratory diseases and included HIV infected participants. STARD =
standards for reporting of diagnostic accuracy; TB = tuberculosis; PTB = pulmonary TB; Mtb =Mycobacterium tuberculosis; OLD = other lung
diseases; HIV = human immunodeficiency virus
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administered intravenous sedatives for conscious sed-
ation. Sedative drugs included midazolam, propofol and
fentanyl, administered on their own or in combination.
Study participants received remuneration of R400
(~30US$) to compensate for loss of time and income.
Participants received a telephonic follow up call at 72 h
and 14 days post bronchoscopy by our research clini-
cians, but did not apply to the OLD cohort since these
participants had clinical indications for bronchoscopies
and were followed up by TBH resident clinicians for
their underlying condition.
Bronchoalveolar lavage
BALF samples were obtained according to international
guidelines [11]. The bronchoscope was inserted through
either nostril or the oral route. Topical lignocaine was
sprayed onto the vocal cords and tracheal bifurcation.
The bronchoscope was targeted to an identified region
of the lung presenting with abnormal or pathologically
suspicious lesions, according to radiological imaging.
Healthy community controls and TB contacts had no
detectable pulmonary lesions according to imaging and
the bronchoscope was targeted to lung regions affording
ease of accessibility. The lung segment was lavaged by
instilling sterile saline solution at 37 °C up to a max-
imum volume of 300 ml in aliquots of 60 ml at a time,
with immediate aspiration between aliquots. TB contacts
received a maximum volume of 200 ml instilled saline
due to specific protocol specifications. Aspirated fluid
retrieved from the BAL procedure was collected in
sterile 50 ml polypropylene tubes and transported on ice
immediately to the laboratory, were BALF samples were
processed within 2 h of collection.
BALF processing and cell isolation
BALC were isolated using centrifugation for 7 min at
300×g following sterile filtration (Falcon® 70 μm Cell
Strainer; Corning Inc., NY). Cells were washed twice
using Phosphate Buffered Saline (PBS) for 5 min at
300×g and viability and cell count determined by Trypan
Blue exclusion method [12].
Differential BALC counts
A differential cell count of total BALC was performed as
previously described with minor modifications [13].
Briefly, isolated suspensions containing 50,000 BALC
was placed on a multi-well microscope slide (Miltitest
Slide, 8 well; MP Biomedicals, LLC, Santa Ana, CA)
covered with Whatman 50 filter paper. Cells were left to
adhere to the slide surface overnight and stained using
Rapidiff Stain Set according to manufacturer’s recom-
mendations. A total of 300–400 cells were manually
counted by light microscopy (Zeiss Axioskop 2). Cells
were classified according to their complexity of morpho-
logical appearances.
Analysis of innate autofluorescent cells by flow cytometry
Approximately 3 × 106 total BALC from a subset of
participants were stained with antibodies for cell surface
receptors to discriminate innate immune cell lineages by
flow cytometry. Briefly, selected antibodies were titrated
to identify the best performing concentration. Compen-
sation and staining controls (fluorescence-minus-one)
were included to account for fluorescence spill-over and
correctly determine positively and negatively stained cell
populations. Controls were prepared using both BALC
and BDCompBead Plus (Becton Dickinson, New Jersey,
USA) for larger cell types. BALC samples were incubated
with fluorescence-conjugated monoclonal antibodies
against CD11b-PerCP and CD33-PE (Becton Dickinson)
for 20 min in 50 μl FACS buffer containing PBS with 5%
fetal calf serum at room temperature and subsequently
washed twice with FACS buffer. These incubations were
performed with or without a quenching procedure using
cellular incubation (5 min on ice) with a crystal violet
solution (2 mg/ml in sodium chloride), before staining
and cell membrane permeabilization (eBiosciences 10x
Permeabilization Buffer; Thermo Fisher Scientific Inc.,
Waltham, MA), as described previously [14]. Stained
BALC were fixed in 4% formaldehyde and immunofluor-
escence signal acquired on a BD FACSCantoII cytometer
using the BD FACSDiva software, version 6.1.2 (Becton
Dickinson). A minimum of 100,000 events were re-
corded during sample acquisition and FCS data analyzed
using FlowJo software (version 10.1, Oregon, USA).
Statistical analysis
Statistical analysis was performed using Statistica 12.0
and GraphPad Prism 7.0 software, with Fisher’s exact
test to examine non-random associations between
categorical variables where appropriate. One-way ana-
lysis of variance (ANOVA) and analysis of co-variance
(ANCOVA) tests (parametric or non-parametric as
appropriate after normality test and Levene’s test for
homogeneity of variance) with Fisher’s least significant
difference (LSD) as post host for all pairwise compari-
sons, were used to compare variables between groups
where suitable. Pearson’s correlation or Spearman’s
rank-order correlation tests (as appropriate following
normality test) were used to determine correlative rela-
tionships between investigated variables.
Results
Patient characteristics
A total of 65 participants initially agreed to undergo
research bronchoscopies, of which 58 underwent the
procedure (Fig. 1). Of the seven participants that did not
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undergo the bronchoscopy, four withdrew consent (three
on the day of planned procedure and one prior) and
three were excluded by the clinical team (two due to ser-
ious co-morbidities and one did not meet study-specific
protocol requirements). Of the 58 participants that
underwent bronchoscopy, 26 were TB cases, 12 healthy
community controls and 20 TB contacts, 12 of which
had DM (Fig. 1). Analysis of isolated BALC pertain to
information collected from samples of a subset of 11
healthy community controls, all OLD participants and
17 TB cases, whose characteristics are described in
Table 1.
Table 2 describes intravenous sedation doses, bron-
choscopy duration and incidental findings at the time of
bronchoscopy for TB, healthy community control, TB
contacts and a combination of all cohorts. Sedatives
used during bronchoscopies were midazolam, fentanyl
and propofol, used in isolation or in combination, as
described in Table 2. The choice of sedative(s) used
depended on the clinician’s preference, study specific
protocol requirements and participants characteristics.
All except two cases received either midazolam in
isolation or a combination of fentanyl and propofol. One
case received a combination of fentanyl and midazolam
and one received only propofol. The total average dose
used for each drug within all reported groups was 5.9
mg, 32.2mcg and 96.1 mg, for midazolam, fentanyl and
propofol, respectively. The average time duration of the
bronchoscopy procedure was 12 min with no substantial
difference noted between TB cases and controls (P = 0.76,
Mann-Whitney U test, Table 2).
Of the 58 participants that underwent bronchoscopy, a
total of four participants had incidental findings at the
time of bronchoscopy (Table 2). Two participants had
vocal cord abnormalities, one had a polyp and one a
nodule and were referred for further assessment. In two
cases, suspicious bronchial lesions were observed. In one
case, a tissue sample was obtained, while the other was
referred for further workup (Table 2).
Pre- and post-bronchoscopy adverse events
Table 3 describes adverse events, complications and
symptoms experienced during and post bronchoscopy
for TB, healthy community controls, TB contacts, and a
combination of all cohorts. None of the participants
presented with serious adverse events. Two participants
experienced complications during the bronchoscopy
procedure. One developed epistaxis, which resolved
prior to hospital discharge, and one presented with
elevated blood pressure readings prior to, throughout,
and post bronchoscopy procedure in a participant not
known with hypertension (Table 3). In one case within
the healthy cohort the bronchoscopy procedure was
aborted and no BALF was retrieved due to distress and
discomfort experienced by the participant, despite ad-
ministration of sedative drugs (Fig. 1). At the 72 h post
bronchoscopy telephonic follow up, 56 of the 58 partici-
pants were contactable. A sore throat was the most
Table 1 Subject characteristics
TB
(n = 17)
Healthy
(n = 11)
OLD
(n = 19)
Demographic
Med age (min-max) 45 (26–58) 28 (20–69)a 46 (27–78)a
Male participant
frequency (%)
70.6b,c 27.3b 26.3c
Smoker frequency (%) 76.5 72.7 63.2
Clinical Diagnosis*, n
Active PTB 16 0 0
PTP w/ extrapulmonary
TB
1 0 0
LRTI 0 0 7
Malignancy** 0 0 6
COPD 2 0 6
Interstitial lung disease 0 0 1
Comorbidities
DM 2 0 2
Rheumatoid arthritis 0 0 1
HIV infection 1 0 6
* Participants from each group (TB, Healthy and OLD) may present with
multiple clinical diagnoses and syndromes
** Includes all forms of malignancies
a indicates significant differences between age and cohort. Significance
determined at P < 0.05 using and one way ANOVA with Fisher’s LSD as post
hoc for all pairwise comparisons
b and c indicate significant differences between gender and cohort.
Significance determined at P < 0.05 using Fisher’s exact test
TB tuberculosis, OLD other lung disease, med median, min minimum, max
maximum, % percent, PTP pulmonary tuberculosis, w/ with, LRTI lower
respiratory tract infection, DM diabetes mellitus, HIV human immunodeficiency
virus, COPD chronic obstructive pulmonary disease
Table 2 Average intravenous sedation doses, bronchoscopy
duration and incidental findings at the time of bronchoscopy
TB
(n = 26)
Healthy
(n = 12)
Contacts
(n = 20)
All Cohorts
(range)
Average intravenous sedation doses
Midazolam (mg) 6.7 0.0 5.1 5.9 (4.0–10.0)
Fentanyl (mcg) 33.6 27.3 35.7 32.2 (12.5–75.0)
Propofol (mg) 101.8 103.3 83.4 96.1 (30.0–250.0)
Average bronchoscopy duration
Time (minutes) 13.0 11.3 12.6 12.0 (7.0–30.0)
Incidental findings (n)
Vocal cord nodule 1 0 0 1 (0–1)
Vocal cord polyp 0 0 1 1 (0–1)
Bronchial lesions 2 0 0 2 (0–2)
TB tuberculosis, Healthy healthy community controls, Contacts household
contacts, mg milligrams, mcg micrograms
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common bronchoscopy-related symptom reported. Six
participants (11%) experienced a sore throat, one of
which also presented with a single episode of vomiting;
and one case reported dizziness; however, symptoms
were resolved by the day 14 telephonic follow up. At the
day 14 telephonic follow up, only one participant pre-
sented with a new symptom namely, a sore throat. None
of the participants required medical attention or hospital
admission for their symptoms (Table 3).
Tolerance and experience of the procedure
Participants from the TB (n = 10) and healthy commu-
nity control (n = 12) cohorts completed a questionnaire
relating to their bronchoscopy experience, as described
in Fig. 2, of which all 22 agreed to partake in the ques-
tionnaire. The majority of participants, (n = 18, 82%)
agreed that the bronchoscopy procedure was tolerable
(Fig. 2a). Twenty (91%) participants reported the bron-
choscopy to be not as bad as expected (Fig. 2b) and 18
(82%) participants reported willingness to undergo an-
other research bronchoscopy in future (Fig. 2c). Reasons
provided for not wanting to undergo a second research
bronchoscopy included discomfort and anxiety related
to the procedure and overall experience.
BALC characteristics: differential cell counts
BALF samples were retrieved from 17 TB cases, 11
healthy community controls and 19 OLD participants
and used for cell isolation. BALC derived therefrom
were evaluated by differential cell count analysis using
light microscopy and differential staining techniques
(Table 4 and Additional file 1: Figure S2; subject charac-
teristics in Table 1).
Statistical analysis was performed in order to evaluate
whether there was a relationship between the colour of
the BALC pellet and smoking status of study partici-
pants. Black BALC pellets were predominant in the
smoking population (P = 0.01) (Fig. 3; also see Fig. 5).
Significant changes in differential BALC counts were
also considered in the context of potential co-variates
such as pellet colour, smoking, endoscopist, gender or
age (Table 1, Additional file 2: Figure S1). There was a
significant difference in the number of bronchoscopies
performed per endoscopist (P = 0.02, Additional file 2:
Figure S1a), meaning that each endoscopist did not
perform the procedure on the same number of patients
in each cohort. However, smoking status (P = 0.21, Add-
itional file 2: Figure S1b) and pellet colour (P = 0.69,
Additional file 2: Figure S1c) show no statistically signifi-
cant differences between cohorts. We report males being
more likely to have TB, relative to females (P = 0.02,
Additional file 2: Figure S1d, Table 1). Additionally,
results show age of healthy community controls to be
significantly lower than the OLD cohort (P = 0.01, Add-
itional file 2: Figure S1e, Table 1).
It was also of interest to determine variations in cellu-
lar data readouts between cohorts including, retrieved
Table 3 Complications during bronchoscopy and post
bronchoscopy symptoms at 72 h follow-up
Symptom During
bronchoscopy
(n = 58)
72 h Post
bronchoscopy
(an = 56)
Participant
Group/s
Sore throat 0 6 (11%) 2 TB, 2 Healthy,
2 Contacts
Vomiting 0 1 (2%) 1 Healthy
Haemoptysis 0 0 –
Epistaxis 1 (2%) 0 1 Healthy
SOB 0 0 –
Cough 0 0 –
Dizziness 0 1 (2%) 1 TB
Elevated BP 1 (2%) 0 1 TB
bDiscomfort 1 (2%) 0 1 Healthy
Total 3 (5%) 8 (14%) 4 TB, 5 Healthy,
2 Contacts
a at 72-h follow-up, 56 of 58 participants were contactable
b bronchoscopy aborted due to participant discomfort, no BALF collected,
participant followed up
TB tuberculosis, Healthy healthy community control/s, Contacts household
contacts, hrs hours, % percentage, SOB shortness of breath, BP blood pressure
Fig. 2 a Tolerability, b) experience, and c) willingness to undergo another bronchoscopy, reported subjectively by participants. A total of n = 22
participants completed a telephonic questionnaire, including n = 10 TB and n = 12 healthy community controls
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BALF/instilled saline ratios, cell yields, cell concentrations,
macrophage/monocyte frequency, neutrophil frequency
and lymphocyte frequency for TB, healthy community
control and OLD cohorts (Table 4, Additional file 1: Fig-
ure S2). Taking significant co-variant data into account
(those being age and gender), we find that BALC yield and
cell concentration (Table 4, Additional file 1: Figure S2b-c)
was greater in TB participants relative to the OLD cohort
(P = 4.19 × 10− 3 and P = 0.05, respectfully). Macrophage/
monocyte frequencies in the TB cohort are significantly
lower than healthy community controls (P = 0.04) and
OLD participants (P = 0.01), with a concomitant increase in
neutrophil frequencies in the TB cohort relative to the
healthy community controls (P = 2.89 × 10− 3) and OLD
patients (P = 1.57 × 10− 3) (Table 4, Additional file 1: Figure
S2d-e). We also show lymphocyte frequencies to be signifi-
cantly lower in TB participants relative to healthy commu-
nity controls (P = 0.03, Additional file 1: Figure S2f).
Irrespective of cohort, correlations were investigated
between volume ratios and cell yield, cell concentration
and age (Additional file 3: Figure S3a-c), as well as corre-
lations between age and cell yield, cell concentration,
monocyte/macrophage frequencies, neutrophil frequen-
cies and lymphocyte frequencies (Fig. 4 and Additional
file 3: Figure S3d-f ). Figure 4 shows significant negative
correlative relationship between macrophage/monocyte
frequencies and age (r = − 0.40; P = 0.01) and a positive
correlative relationship between neutrophil frequencies
and age (r = − 0.49; P = 0.00), irrespective of cohort.
We determined that no statistically significant rela-
tionships exist between cellular readouts (volume ratio,
cell yield, cell concentration, macrophage/monocyte fre-
quency, neutrophil frequency and lymphocyte frequency)
and factors such as pellet colour (Additional file 4: Fig-
ure S4), gender (Additional file 5: Figure S5) and smok-
ing status (Additional file 6: Figure S6).
BALC characteristics: flow cytometric analyses
The flow cytometer was calibrated to account for the
background fluorescence of BALC. BALC from smokers,
demonstrating black BALC pellets (Fig. 5), displayed sig-
nificant autofluorescence (Fig. 6b), when compared to
the non-smoker group with clear BALC (Fig. 6a). BALC
autofluorescence interfered with the detected antibody
fluorescence signal in unquenched and quenched sam-
ples (Fig. 6). Fluorescence spill-over was observed in all
investigated channels, complicating accurate assessment
of cell classifications and frequencies of innate cell types
(data not shown).
Discussion
According to the data presented here, bronchoscopies
with BAL can be considered a safe procedure (outweigh-
ing the benefit-to-risk ratio) with no major complications
Table 4 Evaluation of BALF and BALC form study participants
TB (n = 17) Healthy (n = 11) OLD (n = 19)
Saline and BALF
Med saline volume (ml) in (min-max) 190 (60–300) 170 (120–240) 180 (120–300)
Med BALF volume (ml) out (min-max) 65 (40–125) 90 (45–135) 90 (37–155)
Fluid volume ratio out/in (min-max) 0.31 (0.17–0.67) 0.54 (0.20–0.67) 0.49 (0.12–0.86)
Cellular (based on differential cell counts)
Cell pellet colour (Black/Clear) 12/5 7/4 8/11
Total med BALC count (×106) (min-max) 38.00 (26.40–54.00)a 21.15 (11.25–81.60) 16.20 (6.50–43.40)a
Med BALC concentration (×106/ml) (min-max) 0.68 (0.10–1.39) 0.44 (0.14–1.31) 0.49 (0.12–0.86)
Med % Monocytes/Macrophages (min-max) 81.00 (0.00–88.00)b,c 89.00 (70.00–98.00)b 80.50 (5.00–98.00)c
Med % Neutrophils (min-max) 10.00 (2.00–100.00)d,e 0.00 (0.00–4.00)d 9.00 (0.00–21.00)e
Med % Lymphocytes (min-max) 9.00 (0.00–13.00)f 11.00 (2.00–30.00)f 7.00 (0.00–30.00)
a-f Illustrates statistical differences of data readouts between cohorts. Significance determined at P < 0.05 using ANCOVA with Fisher’s LSD as post hoc for all
pairwise comparisons. Statistical analysis factors in co-variant data of gender and age differences between cohorts
TB tuberculosis, OLD other lung disease, med median, min minimum, max maximum, ml millilitre, % percentage
Fig. 3 BALC pellet colour (black or clear) shown for smoking and
non-smoking study participants. Significance determined at P < 0.05
using Fisher’s exact test
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or adverse events evident in either healthy or diseased par-
ticipants included in this study. Of those partaking in the
post-bronchoscopy survey, 82% of participants described
the procedure as tolerable, with an estimated repeatability
rate of 82%. Only 14% of participants presented with
minor post bronchoscopy symptoms, mainly reports of a
sore throat. These data are comparable to known litera-
ture reporting similar repeatability rates, although Lipman
et al. demonstrated that a higher proportion of partici-
pants (80%) experienced post bronchoscopy symptoms
such as a sore throat [8]. This is likely due to a later evalu-
ation timepoint in our study (72 h vs 24 h), when some
symptoms may have already subsided. However, this ob-
servation may also be influenced by cultural backgrounds
and health-seeking behavior. Furthermore, the average
bronchoscopy procedural time reported by our findings,
from insertion to removal of the bronchoscope, compared
well with a study performed by Grendelmeier et al. [15].
In terms of cellular data derived from BALF, we describe
a strong relationship between pellet colour and smoking
habits, with smoking being associated with yields of black
BALC that strongly interfere with fluorescence-based flow
cytometry analysis techniques. This phenomenon has
previously been described [16, 17]. In light of these find-
ings, we propose an important need for fluorescence-
independent techniques for quantitative phenotypic
analysis of such samples.
Participants for this study were recruited from lower
income communities of the Western Cape province,
with the highest smoking prevalence and TB burden in
South Africa [18]. In line with previously reported statis-
tics and our findings reported here, we suggest that
BAL-derived cellular analysis from smoking participants
of the Western Cape population is not suitable for
fluorescence-based techniques and propose further in-
vestigation into the impact of smoking on host control
of mycobacterial infection at the disease site in the
current population. We report a higher rate of males
(70.6%) and smokers (76%) comprising the TB cohort,
relative to healthy community controls and OLD co-
horts, which are indeed hallmark characteristics that
have been previously reported for TB patients in middle-
Fig. 4 Correlative relationships between a) macrophage frequency and age, b) neutrophil frequency and age. Significance determined at P < 0.05
using Pearson’s correlation or Spearman’s rank-order correlation tests, as appropriate following normality testing
Fig. 5 Exposure to carbonaceous particles from biofuel burning. a Carbon loading was visible as blackened BALC pellets. b Particles were mainly
contained in alveolar macrophages of blackened BALC
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to low-income communities in South Arica [6, 19, 20].
Our data also show a significant difference in age
between cohorts. As such, we report sex and age as co-
variables that are controlled and adjusted for when
reporting differences in cellular data between cohorts.
We report no significant differences of smoking status
and pellet colour between cohorts. This study was not
powered to fully evaluate the propensity for variation
introduced by different endoscopists performing the
bronchoscopy.
Although no significant differences were measured for
fluid volume ratio and cell concentration between
cohorts, total cell yield was increased in the TB cohort
relative to OLD participants. In terms of cellular
Fig. 6 Identification of myeloid cells from BALC samples of TB patients. FSC and SSC characteristics were selected to define all BALC. All
subsequent analyses were performed on cells selected in the BALC gate. a Gating strategy used to define CD11b + CD33+ innate cells from BALC
with low autofluorescence signal. b Gating strategy selected to define CD11b + CD33+ innate cells from BALC presenting with extensive
autofluorescence. c Gating strategy identifying CD11b + CD33+ innate cells from the same BALC indicated in (b), post quenching treatment
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composition of the BALF, we report macrophages/
monocytes to be the predominant BALC population,
with frequencies above 80% for all cohorts, which is in
line with extensive publications reporting macrophages
as the major cell lineage within the BALF [21–24]. Fur-
thermore, we report TB disease to be characterized by
increased neutrophil frequencies and decreased propor-
tions of lymphocytes and macrophages/monocytes in the
BALC compartment. Neutrophils have been described to
be increased and predominant in Mtb-infected regions
of the lung in TB patients, with many studies reporting
neutrophilic infiltration and exorbitant inflammation in
TB disease that is considered to be an overall reflection
of TB disease severity [25–30]. The decrease in macro-
phage/monocyte frequencies in the TB cohort may re-
flect increased numbers and proportions of neutrophilic
populations that predominate in TB patients and thus
translate into decreased macrophage frequency expressed
as a percentage. Alternatively, we could argue in favour of
previously published data that supports the observed
decreased frequency of alveolar macrophage frequencies
in the BALF of TB-infected patients [25, 31, 32]. Another
study proposed the ability of Mtb to hijack macrophages
and promote translocation from the airway to the lung
parenchyma, thus acting as supporting evidence to sub-
stantiate the reported pattern of decreased frequencies
and cell number of airway macrophages within the BALF
of TB-laden individuals, relative to the appropriate con-
trols [33]. Contrary to previous publications that report an
influx of lymphocytes to the site of TB disease, we report
that lymphocytes are reduced in TB participants and
OLD, relative to healthy controls [25, 34, 35]. Notably,
multiple independent studies have reported a significant
tendency of BALC analysis by optical microscopy to
underestimate the percentage of lymphocytes and over-
estimate the frequency of macrophages in the BAL, with
common misinterpretations of stained BAL specimens
due to the propensity of activated cells to resemble other
immune cell lineages [36–40]. In light of these findings,
we conclude discrepant BALC frequencies to previously
reported BALC populations using microscopy-based
differential cell counting, suggesting the value of more
accurate phenotyping approaches such as definitive
antibody-based cell labelling techniques.
We also report that macrophages have a significant
negative relationship with age of the participant, while
neutrophils have a positive relationship with participant
age. This observation is reported irrespective of partici-
pant cohort, however, since macrophage/monocyte and
neutrophil frequencies show significant differences be-
tween cohorts, the significance of the correlative data may
be influenced by different participant groups. We propose
that these findings require validation using more accurate
phenotyping and quantification techniques. Our results
further suggest that black BALC pellets (and the related
tendency to smoking) are characterized by an increase in
macrophage/monocyte populations in the airways relative
to non-smokers, which is in line with several other studies
[41–44]. In line with our findings, several studies have re-
ported no gender-related differences in BALC compos-
ition [45–47].
Limitations to this study include the relatively small
participant group enrolled in this study. We recommend
that the experience questionnaire and cellular data com-
parisons between population groups be studied in a big-
ger cohort in order to better capture data representing
the population at large. We also acknowledge that this
study was limited in its power to determine the effect of
endoscopist variability on cellular data outcomes, which
may certainly be a cofounding factor, depending on ex-
perience, level of expertise and personal preferences in
bronchoscopy proceedings that may lead to variability
in the dataset. Finally, we acknowledge the propensity
for human error and subjective interpretation of
microscopy-based differential counting and highlight
the need for further investigations into BALC charac-
teristics using more objective, accurate means of
cellular phenotyping, using fluorescence-independent
techniques.
Conclusions
We report significantly increased BALC yields, decreased
macrophage/monocyte frequencies, increased neutrophil
frequencies and decreased lymphocyte frequencies in TB
patients, relative to healthy and OLD control cohorts.
Furthermore, macrophage/monocyte frequencies are sig-
nificantly negatively correlated with age, while neutrophils
are significantly positively correlated with age, irrespective
of cohort. We report that smoking is characterized by
black BALC yields and indeed interferes with
fluorescence-based analyses. The data presented here
could be beneficial to researchers designing studies involv-
ing samples derived from bronchoscopy procedures in the
Western Cape population. Researchers may use these data
as a basis for planning, designing and anticipating the
outcomes of research bronchoscopies from the point of
participant recruitment through to BALF processing and
cellular readouts of retrieved samples, which is certainly a
valuable research tool in highly TB-burdened communi-
ties where extensive research is warranted.
Additional files
Additional file 1: Figure S2. Comparison of BALC data readouts
between cohorts. Data readouts: a) volume ratio, b) cell yield, c) cell
concentration, d) macrophage frequency, e) neutrophil frequency and f)
lymphocyte frequency. Significance determined at P < 0.05 and shown in
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red, using ANCOVA with Fisher’s LSD as post hoc for all pairwise
comparisons. (PNG 263 kb)
Additional file 2: Figure S1. The relationship between TB, healthy
community control and OLD cohorts and potential co-variables: a) endoscopist,
b) smoking status, and c) pellet colour, d) gender and e) age; that may affect
cellular BAL data comparisons between cohorts. Significance determined at
P < 0.05, using Fisher’s exact test (a-d) and one-way ANOVA with Fisher’s LSD
as post hoc for all pairwise comparisons (e). (PNG 334 kb)
Additional file 3: Figure S3. Correlative relationships between a)
volume ratio and cell yield, b) volume ratio and cell concentration, c)
volume ratio and age, d) cell yield and age, e) cell concentration and
age, f) lymphocyte frequency and age. Significance determined at P < 0.05,
using Pearson’s correlation or Spearman’s rank-order correlation tests, as
appropriate following normality testing. (PNG 319 kb)
Additional file 4: Figure S4. The relationship between BALC pellet
colour and a) volume ratio, b) cell yield, c) cell concentration, d)
monocyte frequency, e) neutrophil frequency, and f) lymphocyte
frequency. Significance determined at P < 0.05, using one-way ANOVA
tests (parametric or non-parametric as appropriate after normality test
and Levene’s test for homogeneity of variance) with Fisher’s least significant
difference (LSD) as post host for all pairwise comparisons. (PNG 243 kb)
Additional file 5: Figure S5. The relationship between participant
gender and a) volume ratio, b) cell yield, c) cell concentration, d)
monocyte frequency, e) neutrophil frequency, and f) lymphocyte
frequency. Significance determined at P < 0.05, using one-way ANOVA
tests (parametric or non-parametric as appropriate after normality test and
Levene’s test for homogeneity of variance) with Fisher’s least significant
difference (LSD) as post host for all pairwise comparisons. (PNG 240 kb)
Additional file 6: Figure S6. The relationship between participant
smoking status and a) volume ratio, b) cell yield, c) cell concentration, d)
monocyte frequency, e) neutrophil frequency, and f) lymphocyte
frequency. Significance determined at P < 0.05, using one-way ANOVA
tests (parametric or non-parametric as appropriate after normality test and
Levene’s test for homogeneity of variance) with Fisher’s least significant
difference (LSD) as post host for all pairwise comparisons. (PNG 274 kb)
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